Sensitivity and specificity of transferrin saturation and serum ferritin as markers of iron status after intravenous iron dextran in hemodialysis patients

Renal Failure

Volumn 19, Issue 6, 1997, Pages 781-788

  Low, Chai Luan ^a   Bailie, George R ^a,b   Eisele, George ^a  

^a ALBANY COLLEGE OF PHARMACY AND HEALTH SCIENCES   (United States)

^b Department of Neurological Surgery   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ERYTHROPOIETIN; FERRITIN; IRON; IRON DEXTRAN; TRANSFERRIN;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DOSE RESPONSE; FEMALE; FERRITIN BLOOD LEVEL; HEMATOCRIT; HEMODIALYSIS; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MALE; PRIORITY JOURNAL;

EID: 6844254557     PISSN: 0886022X     EISSN: None     Source Type: Journal    
DOI: 10.3109/08860229709037218     Document Type: Article

References (24)

1. Kleiner MJ, Van Wyck DB, Kaupke CJ, et al: The role of iron and other factors in patients unresponsive to erythropoietin therapy. Semin Dialysis 8(1):29-34, 1995.
2. Van Wyck DB, Stivelman JC, Ruiz J: Iron status in patients receiving erythropoietin for dialysis-associated anemia. Kidney Int 35:712-714, 1989.
3. Van Wyck DB: Iron management during recombinant human erythropoietin therapy. Am J Kidney Dis 14(2) Suppl 1:9-13, 1989.
4. Macdougall IC, Hutton RD, Cavill I, et al: Poor response to treatment of renal anemia with erythropoietin corrected by iron given intravenously. Br Med J 299:157-158, 1989.
5. Fishbane S, Frei GL, Maesaka J: Reduction in recombinant human erythropoietin doses by the use of chronic intravenous iron supplementation. Am J Kidney Dis 26(I):41-46, 1995.
6. Taylor JE, Peat N, Porter C, et al: Regular low-dose intravenous iron therapy improves response to erythropoietin in haemodialysis patients. Nephrol Dial Transplant 11:1079-1083, 1996.
7. Silverberg DS, Blum M, Peer G, et al: Intravenous ferric saccharate as an iron supplement in dialysis patients. Nephron 72:413-417, 1996.
8. Sepandj F, Jindal K, West M, et al: Economic appraisal of maintenance parenteral iron administration in treatment of anaemia in chronic haemodialysis patients. Nephrol Dial Transplant 11:319-322, 1996.
9. Macdougall IC, Tucker B, Thompson J, et al: A randomized controlled study of iron supplementation in patients treated with erythropoietin. Kidney Int 50:1694-1699, 1996.
10. Ahsan N, Groff JA, Waybill MA: Efficacy of bolus intravenous iron dextran treatment in peritoneal dialysis patients receiving recombinant human erythropoietin. Adv Perit Dial 12:161-166, 1996.
11. Silverberg DS, Iaina A, Peer G, et al: Intravenous iron supplementation for the treatment of anemia of moderate to severe chronic renal failure patients not receiving dialysis. Am J Kidney Dis 27(2):234-238, 1996.
12. Anastassiades EG, Howarth D, Howarth J, et al: Monitoring of iron requirements in renal patients on erythropoietin. Nephrol Dial Transplant 8:846-853, 1993.
13. Kooistra MP, van Es A, Struyvenberg A, et al: Iron metabolism in patients with the anemia of end-stage renal disease during treatment with recombinant human erythropoietin. Br J Haematol 79:634-639, 1991.
14. Jacobs A, Worwood M: Ferritin in serum: clinical and biochemical implications. N Engl J Med 292(18): 950-956, 1975.
15. Bell JD, Kincaid WR, Morgan RG, et al: Serum ferritin assay and bone-marrow iron stores in patients on maintenance hemodialysis. Kidney Int 17:237-241, 1980.
16. Cook JD: Clinical evaluation of iron deficiency. Semin Hematol 19(1):6-18, 1982.
17. Staland BE, Winkel P: Relationship of day-to-day variation of serum iron concentrations to iron-binding capacity in healthy young women. Am J Clin Path 67:84-90, 1977.
18. Skikne BS, Flowers CH, Cook JD: Serum transferrin receptor: a quantitative measure of tissue iron deficiency. Am J Hematol 75:1870-1876, 1990.
19. Kohgo Y, Niitsu Y, Kondo H, et al: Serum transferrin receptor as a new index of erythropoiesis. Blood 70:1955-1958, 1987.
20. Fishbane S, Lynn RI: The utility of zinc protoporphyrin for predicting the need for intravenous iron therapy in hemodialysis patients. Am J Kidney Dis 25(3):426-432, 1995.
21. Scaffer RM, Schaefer L: The hypochromic red cell: a new parameter for monitoring of iron supplementation during rhEPO therapy. J Perinat Med 23:83-88, 1995.
22. Macdougall IC: Poor response to erythropoietin: practical guidelines on investigation and management. Nephrol Dial Transplant 10:607-614, 1995.
23. Fishbane S, Galgano C, Maesaka JK: Reticulocyte hemoglobin content in the diagnosis of iron deficiency in hemodialysis patients. J Am Soc Nephrol 7(9):(Abstract) 1479, 1996.
24. Horl WH, Cavill IC, Macdougall RM, et al: How to diagnose and correct iron deficiency during r-huEPO therapy - a consensus report. Nephrol Dial Transplant 11:246-250, 1996.